Yes. Eltrombopag can help raise a low platelet count in certain conditions by signaling the bone marrow to make more platelets. Doctors use it for some people with persistent or chronic immune thrombocytopenia (ITP) and for selected cases of aplastic anemia; it is not suitable for every cause of low platelets. Treatment requires blood tests because too many platelets and liver problems are possible.
Eltrombopag is a prescription medicine that helps the body produce more platelets, which are blood cells needed for clotting. Whether it is appropriate depends on why the platelet count is low, the person's medical history, previous treatments, and the risk of bleeding.
How does eltrombopag help increase platelets?
Eltrombopag belongs to a group of medicines called thrombopoietin receptor agonists. It activates a receptor involved in platelet production, encouraging the bone marrow to produce more platelets. This can help increase the number of platelets circulating in the blood.
According to the U.S. National Library of Medicine's MedlinePlus drug information, eltrombopag stimulates platelet production in the bone marrow. However, an increase in platelet count does not mean that the underlying condition has been cured. Some people respond well to treatment, while others may not achieve enough of an increase.
The aim is generally to raise the platelet count enough to reduce the risk of bleeding, rather than to force the count into the normal range. A healthcare professional adjusts treatment according to the response and potential risks.
Which conditions can eltrombopag treat?
Eltrombopag is used for particular medical conditions rather than for every instance of thrombocytopenia, the medical term for a low platelet count. The U.S. Food and Drug Administration's prescribing information describes its approved uses in specific situations involving immune thrombocytopenia, severe aplastic anemia, and thrombocytopenia associated with chronic hepatitis C when interferon-based treatment is planned.
Immune thrombocytopenia (ITP)
ITP is a condition in which the immune system destroys platelets, leading to a lower platelet count. Eltrombopag can help some adults and children with persistent or chronic ITP when other treatments, such as corticosteroids or immunoglobulins, have not worked adequately. In some patients, it can help maintain a platelet count that reduces bleeding risk.
It is not automatically the first treatment for everyone with ITP. The American Society of Hematology's ITP clinical practice guidelines address treatment choices that depend on the patient's circumstances and previous response to treatment. Eltrombopag may be considered when a suitable treatment is needed to manage persistent or chronic disease.
Severe aplastic anemia
Aplastic anemia is a condition in which the bone marrow does not produce enough blood cells. This can affect platelets as well as red and white blood cells. In certain patients with severe aplastic anemia, eltrombopag is used alongside standard immunosuppressive treatment or when the response to previous immunosuppressive therapy has been inadequate.
Its role in aplastic anemia is broader than simply treating an isolated low platelet count because the underlying problem involves blood cell production. The treatment plan depends on the person's age, blood counts, medical condition, and response to other therapies.
Thrombocytopenia associated with chronic hepatitis C
Eltrombopag also has a specific approved use for certain people with chronic hepatitis C whose platelet counts interfere with planned interferon-based antiviral treatment. This is a particular treatment setting, not a recommendation to use eltrombopag for every person with hepatitis C or liver disease and low platelets. Liver health is especially important when considering this medicine because it can cause liver injury.
Can eltrombopag help every cause of low platelets?
No. A low platelet count can have many possible causes, including immune-related conditions, infections, medication effects, liver disease, and problems affecting the bone marrow. Treatment that helps one cause may not help another.
The National Heart, Lung, and Blood Institute's information on thrombocytopenia explains that treatment depends on the cause and circumstances of the low platelet count. Eltrombopag may be considered when the underlying condition and treatment goals make it appropriate, but it is not a general treatment for every abnormal platelet result.
Before recommending eltrombopag, a healthcare professional considers the complete blood count, trends in platelet levels, symptoms, medical history, current medicines, and any relevant liver or bone marrow conditions. A single low result does not by itself establish that this medicine is needed.
How quickly can eltrombopag raise platelet counts?
The time needed to see a response varies by the condition being treated and the individual person's response. In clinical trials involving ITP, platelet counts generally began to increase within one to two weeks of starting treatment. This is not a guarantee that everyone will respond within that period, and responses in other conditions can follow a different course.
Regular blood tests help the prescriber determine whether the medicine is working and whether the dose needs adjustment. If the platelet count does not improve enough, the healthcare professional may reconsider the treatment plan rather than increasing the dose without limits.
How is eltrombopag taken and monitored?
Eltrombopag is taken by mouth as tablets or an oral suspension. The prescribed dose depends on the condition being treated and individual factors such as age and liver function. Adults and children may require different treatment plans, so children should receive this medicine under appropriate specialist supervision.
The medication must be taken according to the prescription and product instructions. Food and certain minerals can interfere with its absorption. Depending on the formulation and instructions, it is generally taken on an empty stomach, with the required spacing from calcium-rich foods and products containing calcium, iron, magnesium, aluminum, zinc, or other interacting minerals. A pharmacist can help arrange a safe schedule around meals and other medicines.
Monitoring is an important part of treatment. Your healthcare professional may order:
- Regular complete blood counts, including platelet counts, to track the response and identify excessive increases.
- Liver function tests before and during treatment to check for possible liver injury.
- Eye examinations, when indicated by the prescribing guidance, because changes such as cataracts are a recognized concern.
Platelet counts may fall again after eltrombopag is stopped. Do not change the dose or discontinue treatment on your own. The prescriber can advise when to repeat blood tests and whether any change in treatment is needed.
What are the risks and side effects of eltrombopag?
Eltrombopag can cause side effects. Some people experience headache, tiredness, cough, fever, nausea, or diarrhea. Not everyone experiences these effects, and their significance depends on the person's overall health and treatment plan.
More serious risks include liver injury and blood clots. Raising platelet counts too much can increase the risk of clotting, and clotting complications have also been reported at low or normal platelet counts. Cleveland Clinic's eltrombopag medication guidance emphasizes the need for regular monitoring, awareness of possible side effects, and discussion of medical conditions that could affect treatment safety.
The FDA prescribing information also warns that eltrombopag can cause potentially serious liver problems and that liver function should be monitored. Seek prompt medical attention for signs such as yellowing of the skin or eyes, unusually dark urine, or pain in the upper right part of the abdomen. Sudden chest pain, difficulty breathing, one-sided leg swelling, or sudden weakness or difficulty speaking may indicate an emergency and require immediate care.
Tell the prescriber about any history of blood clots, liver disease, eye problems, pregnancy, breastfeeding, and all prescription medicines, over-the-counter products, vitamins, and supplements. This information can affect the safety and suitability of treatment.
When should you discuss eltrombopag with a healthcare professional?
Discuss treatment options with a healthcare professional if platelet counts remain lower than expected, particularly when the cause is unclear or the results are changing over time. Eltrombopag may be an option for certain diagnosed conditions, but the decision should be based on the cause of thrombocytopenia, bleeding risk, other treatments, and the person's overall health.
Unusual or persistent bleeding, new or unexplained bruising, or a worsening pattern of bleeding deserves medical assessment. Heavy bleeding that will not stop, vomiting blood, black or bloody stools, or sudden severe neurological symptoms require urgent medical care. People already taking eltrombopag should follow their individual monitoring plan and report concerning symptoms without waiting for the next routine appointment.